Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE·NASDAQ

$84.19

+3.0%
HealthcareBiotechnology

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$5.21B
EPS-4.2200
P/E Ratio-19.95
Earnings Date08/10/2026

apge

Total Non-Current Assets

Last Annual Value

195.78M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. Competitors Analysis of Total Non-Current Assets

APGE · NASDAQ
CompanyTotal Non-Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
195.78M
302.8%N/AN/A 
486.60M
11.5%23.5%N/A
581.00M
-8.5%-2.7%29.9%
32.12M
83.7%157.3%N/A
CELC logo
Celcuity Inc.
NASDAQ:CELC
899.00K
12.7%10.2%20.0%
2.98M
8.5%9.1%N/A
208.02M
181.4%73.8%61.1%
Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. Fair Value Envelope

APGE · NASDAQ

Our analysis suggests that APGE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $84.19, this represents a potential HIDDEN relative to our calculated worth for Apogee Therapeutics, Inc..

Intrinsic Value
Current Price: $84.19